SMAD3 and breast carcinoma: Mo et al. reported that the overexpression of tRF-17-79MP9PP in breast cancer cells weakened thrombospondin-1-mediated TGF-β1/SMAD3 signaling, suggesting that it may be a potential therapeutic target for breast cancer [19].